Skip to content
Careers
Contact Us
Linkedin
Twitter
Search for:
Home
About
The COUR Team
Medical & Science Partners
Product Development
Pipeline
CNP-101/TAK-101 (Celiac Disease)
CNP-201 (Peanut Allergy)
CNP-104 (Primary Biliary Cholangitis)
CNP-T1D (Type 1 Diabetes)
CNP-MYG (Myasthenia Gravis)
CNP-ITP (Immune Thrombocytopenia Purpura)
Technology
COUR Nanoparticle Platform
Immune Reprogramming
Therapeutic Areas
Autoimmune Diseases: Celiac
Food & Environmental Allergies: Peanut Allergy
Rare Diseases: Primary Biliary Cholangitis
Autoimmune Diseases: Type 1 Diabetes
Rare Diseases: Myasthenia Gravis
Rare Diseases: Immune Thrombocytopenia Purpura
Protein Replacement: Gene Therapy
Partners & Collaborators
Media & Publications
Press Releases
Scientific Publications
Videos
Technology
Autoimmune Disease
Food and Environmental Allergies
Gene Therapy
COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer
COUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer
Post navigation
COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis
COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model
